Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus
Indexed incrossref
Abstract
Background — Elevated urine albumin excretion (UAER) is a modifiable risk factor for renal and cardiovascular disease in type 2 diabetes. Blockade of the renin-angiotensin system lowers UAER, but whether this effect is independent of blood pressure (BP) reduction remains controversial. The MicroAlbuminuria Reduction With VALsartan (MARVAL) study was designed to evaluate the BP-independent effect of valsartan on UAER in type 2 diabetic patients with microalbuminuria. Methods and Results — Three hundred thirty-two patients with type 2 diabetes and microalbuminuria, with or without hypertension, were randomly assigned to 80 mg/d valsartan or 5 mg/d amlodipine for 24 weeks. A target BP of 135/85 mm Hg was aimed…
Citation impact
807
total citations
- FWCI
- 39.32
- Percentile
- 100%
- References
- 40
Citations per year
Authors
2Topics & keywords
Topics
Keywords
- Medicine
- Microalbuminuria
- Valsartan
- Amlodipine
- Internal medicine
- Blood pressure
- Doxazosin
- Type 2 diabetes
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.